Skip to main content
logo
Faeth Therapeutics, Inc. (FTH)
NASDAQ: FTH · Real-Time Price · USD
41.06
+1.01 (2.52%)
Sep 8, 2026, 11:10 AM EDT - Market open

Faeth Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
18.8211.3313.0418.7719.8115.82
Research & Development
17.9410.9618.6318.330.3821.66
Operating Expenses
36.7622.2931.6637.0650.1937.48
Operating Income
-36.76-22.29-31.66-37.06-50.19-37.48
Interest Expense
-0.03-0.03-0.09-0.14-0.22-0.67
Interest & Investment Income
3.191.242.553.621.780.8
Other Non Operating Income (Expenses)
-1.22-0.7-0.99-1.270.250.61
EBT Excluding Unusual Items
-34.83-21.78-30.19-34.86-48.37-36.75
Gain (Loss) on Sale of Investments
1.380.70.991.06-0.22-0.62
Gain (Loss) on Sale of Assets
-0.02-0--0.3--
Asset Writedown
---0.95---
Other Unusual Items
-15.6----0.57
Pretax Income
-195.53-21.09-30.16-34.1-48.59-36.79
Earnings From Continuing Operations
--21.09-30.16-34.1-48.59-36.79
Net Income
-195.53-21.09-30.16-34.1-48.59-36.79
Net Income to Common
-195.53-21.09-30.16-34.1-48.59-36.79
Net Income Growth
------
Shares Outstanding (Basic)
211121
Shares Outstanding (Diluted)
211121
Shares Change
88.34%0.40%-10.15%-8.96%10.80%1618.88%
EPS (Basic)
-82.46-16.72-24.01-24.40-31.65-26.56
EPS (Diluted)
-82.46-16.72-24.01-24.40-31.65-26.56
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-33.86-20.47-24.82-32.2-39.35-32.29
Free Cash Flow Per Share
-14.28-16.23-19.76-23.04-25.63-23.30
EBITDA
-36.64-22.15-30.34-35.71-48.84-36.8
D&A For EBITDA
0.120.141.321.351.350.69
EBIT
-36.76-22.29-31.66-37.06-50.19-37.48
SEC Filings: 10-K · 10-Q